First Successful Phase 3 In Vivo Gene Editing Offers Hope for a Cure for Hereditary Angioedema
Intellia Therapeutics' lonvo-z therapy met all endpoints in the HAELO trial, reducing the mean monthly attack rate to 0.26 compared to 2.10 in the placebo group. This is the first time in history that gene editing directly inside the human body has proven effective in a final-stage trial.
First Successful Phase 3 In Vivo Gene Editing: Intellia Therapeutics Ushers in a New Era of Medicine
Introduction
On April 27, 2026, Intellia Therapeutics announced results that can be described as historic without exaggeration: the therapy lonvoguran ziclumeran (lonvo-z) successfully met all primary and secondary endpoints in the Phase III HAELO study in patients with hereditary angioedema (HAE). This is the first time in the world that gene editing directly inside the human body (in vivo) has demonstrated efficacy in the final, registration-stage clinical trial. The event marks the transition of CRISPR/Cas9 technology from promising experiments to practical therapeutic reality.
Event Details and Timeline
The HAELO study was a randomized, double-blind, placebo-controlled clinical trial involving 80 patients aged 16 years and older with HAE type I or II. 52 participants received a single intravenous infusion of lonvo-z, 28 received placebo. The drug targets the KLKB1 gene, whose inactivation reduces the production of kallikrein and bradykinin—the molecule directly responsible for swelling attacks.
The results were impressive. During the primary evaluation period (weeks 5–28 post-infusion), the mean monthly attack rate in the lonvo-z group was 0.26 versus 2.10 in the placebo group—an 87% reduction (P < 0.0001). But even more telling is another parameter: 62% of patients receiving lonvo-z were completely attack-free throughout the six-month evaluation period, compared to only 11% in the placebo group (odds ratio 12.8; 95% CI 3.5–47.6; P < 0.0001).
The study design included a crossover after week 28: placebo patients received lonvo-z, and vice versa. Early data from the crossover phase show that those who switched to lonvo-z experienced a rapid reduction in attack rates to nearly zero. All patients who received therapy (initially or upon crossover) completely discontinued long-term prophylactic therapy.
Safety was excellent: no serious adverse events were reported in the lonvo-z group, and no grade 3 or higher adverse events. The most common side effects were infusion reactions (62%), headache (19%), fatigue (14%), and nasopharyngitis (14%)—all mild or moderate.
Concurrently with the announcement, Intellia initiated a rolling submission of a Biologics License Application (BLA) to the FDA, planning to complete it in the second half of 2026 and launch commercially in the US in the first half of 2027.
Impact and Significance
The significance of HAELO extends far beyond a single disease. First, it validates the very concept of in vivo CRISPR editing. Previous approved CRISPR-based therapies (e.g., Casgevy from Vertex/CRISPR Therapeutics for sickle cell disease) used an ex vivo approach: cells were removed from the patient, edited in the lab, and returned. Lonvo-z works directly inside the human body—a fundamentally different level of technological complexity and potentially a much broader range of applications.
Intellia's President and CEO John Leonard characterized it this way: "As the first Phase 3 data for an in vivo gene editing therapy, today's HAELO results represent a critical milestone for Intellia, the broader CRISPR and precision medicine field, and most importantly, for the HAE patient community."
Second, the treatment paradigm for HAE is changing. Today, patients must undergo chronic therapy—injectable or oral—for decades, which does not completely eliminate the risk of breakthrough attacks. A single infusion that potentially eliminates attacks for life represents a radical shift.
Third, significant commercial potential opens up. Analysts predict that lonvo-z sales could exceed $500 million by 2030. The global HAE therapy market is estimated at $6.3 billion. Intellia's total addressable market, including its second candidate (nex-z for ATTR amyloidosis), could reach $23 billion.
Fourth, a regulatory precedent is being set. Intellia holds Regenerative Medicine Advanced Therapy (RMAT) and orphan drug designations for lonvo-z, and participated in the FDA's pilot program for chemistry, manufacturing, and controls—all of which, according to BofA analysts, positively impact regulatory prospects.
Key Stakeholder Reactions
Financial markets reacted mixedly. Intellia shares rose 25% ahead of the data announcement, and after the results were published, the price increased another 4.6%, with a year-to-date return of 64.34%. However, the day after the announcement, the company conducted a secondary offering of $180 million at $10.75 per share, causing shares to fall 15.1%. This is a classic biotech scenario: strong scientific data coexisting with dilution of existing shareholders.
BofA Securities analysts raised their price target to $20 with a "neutral" rating, increasing the probability of success for the HAE program from 60% to 75%. At the same time, analysts noted that the attack rate reduction "is within the range of competitors but not obviously superior"—a hint that commercial success will depend on physicians' willingness to switch stable patients from familiar prophylactic therapy to experimental gene editing.
As of early May 2026, shares traded at $13.87, with an implied fair value of $26.80 according to analysts. In other words, the market acknowledges the breakthrough potential of the technology but remains skeptical about the timing and scale of commercialization.
Forecast and Conclusions
The HAELO results create a solid foundation for several interrelated trends. First—a wave of similar studies from competitors. Now that Intellia has demonstrated the feasibility of in vivo CRISPR editing in a registration trial, other companies will accelerate development. This will speed progress but also intensify competition.
Second—regulatory evolution. The FDA has never approved an in vivo CRISPR therapy before. The upcoming decision will set a precedent for the entire industry. If the BLA is approved (launch planned for first half of 2027), it will create a regulatory pathway for dozens of other programs.
Third—the question of payment for a "one-time cure." Gene editing therapies are likely to be expensive—possibly in the range of $2–3 million per course. However, proponents argue that chronic HAE treatment with existing drugs costs hundreds of thousands of dollars annually, and over 10–15 years, a one-time intervention could be more cost-effective.
Fourth—the question of long-term safety. Patient follow-up in HAELO continues, and data on durability of effect after 2–3 years or more will be critical for clinical community acceptance. So far, results are encouraging, but in vivo genome editing carries theoretical risks of off-target modifications, whose consequences may appear years later.
In summary: April 27, 2026 is a date that will enter medical genetics textbooks. Intellia Therapeutics did not just successfully complete a Phase 3 for one drug. It proved that CRISPR can work as a medicine directly inside the human body. For patients with hereditary angioedema, this means real hope for a life without constant fear of the next attack. For the industry, it opens a new therapeutic modality, comparable in significance to the advent of monoclonal antibodies. And for society, it is another step toward a future where genetic diseases are treated not symptomatically but at the root cause, with a single infusion.
— Editorial Team
